Abstract
Personalized dosimetry as a key for optimizing radioligand therapy (RLT) with 177Lu- or 177Lu/90Y-DOTA-TATE in patients with well-differentiated neuroendocrine tumors - an update on the initial results of the DUONEN multicenter study
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have